- Personalised vaccines from neoantigens using dendritic cells as targets for activation could radically improve overall survival.1
Why this matters
- Most patients with ovarian cancer (85%) relapse after first-line treatment.
- Intratumoral T cells have been found to be present in 55% of ovarian tumours.
- Very few grade 3-4 adverse events.
- Clinical response correlated with immune response (IFN).
- T-cell responses induced by the vaccine were polyfunctional.
- Conclusions on personalised whole tumour antigen vaccines:
- Induce responses that correlate with progression-free survival.
- 2-year overall survival (OS) rates of the responder patients were 100%, whereas the 2-year OS of non-responders were 25%.2
- Must be combined with standard of care immunomodulatory treatment (bevacizumab and cyclophosphamide) for added synergistic effect.
- Enhanced pre-existing response against some neo-epitopes and induced newly detected responses against additional neo-epitopes.
- Have potential in patients with low mutational load for which a sufficient amount of tumour is available to produce the vaccine.
- Phase 1 clinical trial of autologous dendritic cell vaccine loaded with autologous tumour cell lysate for recurring ovarian cancer.
- The immunogenicity of tumour cells was optimised by exposing them to hypochlorous acid.
- Administration was by intra-nodal injection.
- Average 16 doses per patient and 174 intranodal injections.
- Very small, early stage study.